Great Lakes Hemophilia Foundation’s (GLHF) 4th annual Madison’s Best Bloody contest will be held Sunday, February 25 from 11:30 am until 3 pm. Madison area bars and restaurants enjoy the opportunity to give back in a fun,…
En EspañolInhibitors can take a toll on your physical and emotional well-being, and it can also be very expensive. There are different ways of managing inhibitors. While some individuals prefer treating with emicizumab (Hemlibra®), despite having an…
En EspañolIndividuals who have inhibitors are more likely to be hospitalized than individuals who do not have an inhibitor. Preparation can be key when it comes to emergencies and visiting the emergency room (E.R.).Remember to advocate for yourself…
Takeda announced today that it is conducting a voluntary market withdrawal for two product lots of 650 IU VONVENDI® [von Willebrand factor] in the U.S. Takeda said that the withdrawal is being conducted out of an abundance of caution due to…
In recent years, the arrival of novel hemophilia treatments that are effective and less burdensome to administer have opened up new possibilities for the consumers of these therapies. This begs the question – How might this evolving landscape be…
En Español
Celebrate Black History Month with NBDF!
This year we will share stories from the Black community within the bleeding disorders community. These individuals are truly an inspiration to the entire inheritable blood and bleeding disorders…
For Immediate ReleaseCONTACT:Carrie L. StrehlauNational Bleeding Disorders Foundationcstrehlau@hemophilia.org901-230-4665National Bleeding Disorders Foundation Names Phil Gattone, M.Ed., Next Chief Executive Officer…
Novo Nordisk recently informed NBDF that they are experiencing a temporary shortage of their product Rebinyn®, specifically in the 3,000 IU vial size. Rebinyn is a recombinant factor IX extended half-life therapy for the treatment of hemophilia B…
*Note: Please click cc to activate the close captions for this video. Join us for a discussion on the science and mechanism around neurostimulation for hemostasis, and pre-clinical evidence for hemophilia A and B. The panel will also…